Tenderwize
Zurück zur Suche

Open House Originale Agreement for Tacrolimus (Retard Tablets)

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 276 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-15 - Tacrolimus (Retardtabletten)

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

The notice contains multiple end-date representations (structured data, XML notice, and timezone variants). This create...

Eligibility is restricted to pharmaceutical manufacturers with the required seat, authorisation, and reliability declar...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of pharmaceutical products, specifically Tacrolimus (retard tablets).
  • Open House original rebate agreements under Section 130c(1) SGB V.
Vollständige Zusammenfassung anzeigen

Open House supply arrangement for Tacrolimus (retard tablets) in Germany, led by Techniker Krankenkasse with HEK and hkk as participating buyers. The notice states that any suitable pharmaceutical manufacturer may join during the contract period, but only if it meets the stated legal and reliability conditions and provides the required self-declarations. No contract value is stated. Electronic submission via the portal is not allowed; contracts must be submitted by email with qualified electronic signature or by post, and the procurement documents are available electronically but were not analyzed in extracted text beyond the notice XML.

Risiken

The notice contains multiple end-date representations (structured data, XML notice, and timezone variants). This create...

Eligibility is restricted to pharmaceutical manufacturers with the required seat, authorisation, and reliability declar...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical manufacturer within the meaning of Section 4(18) AMG for the relevant medicinal product.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant product and/or otherwise be entitled to place it on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Originale Agreement for Tacrolimus (Retard Tablets)

Supply arrangement for Tacrolimus (retard tablets) under an Open House procedure. Scope is nationwide in Germany. The lot information comes from structured data and XML notice. No lot value is stated. The contract can be joined at any time during the contract period, subject to eligibility and document requirements.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Frist

Deadline May 30, 2027

Vergabedetails

Veröffentlichungsdatum
21 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
260054-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3